```html

Ileal Pouchitis – A Complete Patient Guide

Overview

Ileal pouchitis (often simply called “pouchitis”) is an inflammation of the iliac-anal reservoir (the “J‑pouch”) that is surgically created after a total proctocolectomy for ulcerative colitis (UC) or, less commonly, familial adenomatous polyposis (FAP). The pouch is made from the terminal ileum and functions as a new rectum, allowing stool to be stored and expelled through the anus.

Key points:

• Who it affects: Almost exclusively patients who have undergone a restorative proctocolectomy with ileal pouch‑anal anastomosis (IPAA). Most patients are adults (median age ≈ 30‑45 y) but it can occur in adolescents and, rarely, in older adults.
• Prevalence: Pouchitis is the most common long‑term complication after IPAA. Reported incidence ranges from 15‑45 % within 5 years of surgery and up to 70 % in lifetime follow‑up studies.<sup>1,2</sup>
• Typical course: Many patients experience a single episode that resolves with antibiotics; however, up to 30 % develop chronic or recurrent pouchitis, requiring long‑term management.

Symptoms

Symptoms may be mild (similar to a short‑lasting “gastritis”) or severe enough to impair daily life. Because the pouch replaces the rectum, many complaints relate to bowel function.

• Frequent watery or soft stools – often 6‑12 per day; urgency is common.
• Abdominal cramping or lower‑abdomen pain – typically vague, described as a “tightness” around the pelvic area.
• Urgency and incontinence – the urge to defecate may be overwhelming, sometimes leading to accidental leakage.
• Fever – low‑grade (37.5‑38.5 °C) is typical; high fever suggests infection or another complication.
• Rectal bleeding – usually mild; bright red blood may accompany a flare.
• Fecal urgency at night – can disrupt sleep.
• Tenesmus – feeling of incomplete emptying after a bowel movement.
• General malaise, fatigue, weight loss – more common in chronic disease.
• Pouch “noisy” or “gurgling” sounds – simply a sign of increased motility.
• Joint pain or peripheral arthritis – an extra‑intestinal manifestation that can accompany pouchitis.

Causes and Risk Factors

The exact pathophysiology is not completely understood, but several mechanisms overlap:

1. Microbial dysbiosis – an imbalance of normal gut bacteria appears to trigger inflammation. Studies have shown reduced diversity and over‑growth of certain anaerobes in pouchitis patients.<sup>3</sup>
2. Immune dysregulation – patients with ulcerative colitis already have a hyper‑reactive mucosal immune system, which may continue to attack the ileal pouch.
3. Ischemia or mechanical factors – poor blood flow or tension on the anastomosis can predispose to inflammation.
4. Genetic predisposition – certain HLA types (e.g., HLA‑DRB1*01) have been associated with recurrent pouchitis.<sup>4</sup>

Risk Factors

• History of primary sclerosing cholangitis (PSC) – patients with PSC have a 2‑3× higher risk of chronic pouchitis.<sup>5</sup>
• Pre‑operative extensive ulcerative colitis (especially with backwash ileitis).
• Smoking – associated with higher rates of pouch failure and inflammation.
• Antibiotic use before or after surgery that disrupts normal flora.
• Female sex – some series suggest slightly higher incidence, possibly related to pelvic anatomy.
• Non‑adherence to post‑operative surveillance (e.g., missed endoscopic exams).

Diagnosis

Because many symptoms overlap with other pouch disorders (e.g., cuffitis, Crohn’s disease of the pouch, or infectious colitis), a systematic approach is required.

1. Clinical Evaluation

• Detailed history of stool frequency, consistency, urgency, and systemic symptoms.
• Physical exam focusing on abdominal tenderness, perianal skin, and any signs of systemic infection.

2. Laboratory Tests

• Stool studies – culture, ova & parasites, Clostridioides difficile toxin PCR to rule out infection.
• Inflammatory markers – C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) may be elevated.
• Serological tests – anti‑Saccharomyces cerevisiae antibodies (ASCA) can help differentiate Crohn‑like disease.

3. Endoscopic Examination (Pouchoscopy)

The gold standard. A flexible endoscope is passed through the anus into the pouch to visualize and obtain biopsies.

• Typical endoscopic findings: erythema, friability, mucosal edema, ulcerations, or pseudopolyps.
• Biopsies are graded using the Pouchitis Disease Activity Index (PDAI) – a score ≥7 indicates active pouchitis.<sup>6</sup>

4. Imaging (optional)

• Pelvic MRI or CT – reserved for suspected complications such as abscess, fistula, or Crohn’s disease of the pouch.
• Small‑bowel contrast studies – can assess pouch anatomy if obstruction is suspected.

Treatment Options

Treatment is guided by severity (acute vs. chronic) and underlying cause (infectious vs. idiopathic).

1. Acute (First‑Episode) Pouchitis

First‑line therapy is a short course of antibiotics, which targets the dysbiotic bacteria.

Antibiotic	Typical Regimen	Notes
Metronidazole	500 mg PO q8h for 2‑4 weeks	Effective but may cause peripheral neuropathy with prolonged use.
Ciprofloxacin	500 mg PO q12h for 2‑4 weeks	Often combined with metronidazole for synergistic effect.
Rifaximin	550 mg PO q12h for 2‑4 weeks	Minimal systemic absorption; useful in patients with fluoroquinolone intolerance.

Clinical response is usually seen within 7‑10 days. If symptoms improve, the antibiotic course can be completed; if not, consider repeat pouchoscopy or step‑up therapy.

2. Recurrent or Chronic Pouchitis

Defined as ≥3 episodes per year or continuous symptoms despite antibiotics.

• Rotating or prophylactic antibiotics – e.g., metronidazole 5 days/month plus ciprofloxacin 5 days/month.
• Probiotics – VSL#3 (high‑dose multi‑strain) has shown efficacy in maintaining remission in several RCTs (NNT ≈ 5).<sup>7</sup>
• Biologic agents – Anti‑TNF (infliximab, adalimumab) or anti‑integrin (vedolizumab) for patients with Crohn‑like pouchitis or refractory disease.
• Bud​esonide enemas – 2 mg/25 mL rectally nightly for 2‑4 weeks can reduce local inflammation.
• Fecal microbiota transplantation (FMT) – emerging therapy; early studies suggest remission rates of 40‑60 % in refractory cases.<sup>8</sup>

3. Surgical Options (last resort)

• Pouch revision – removal of inflamed mucosa; typically reserved for isolated ulcerations.
• Pouch excision with ileostomy – considered when pouch function is non‑viable or when chronic inflammation leads to dysplasia or severe pelvic sepsis.

4. Lifestyle & Adjunct Measures

• Low‑FODMAP or low‑residue diet to reduce gas and urgency (individualized).
• Hydration – aim for 2‑3 L/day to compensate for fluid loss.
• Regular physical activity – improves bowel motility and overall well‑being.
• Avoid smoking and limit alcohol, both of which can exacerbate inflammation.

Living with Ileal Pouchitis

Successful long‑term management combines medical therapy, self‑monitoring, and lifestyle tweaks.

• Symptom diary – record stool frequency, consistency (Bristol Stool Chart), urgency, and any triggers.
• Medication adherence – set alarms or use pill‑organizers for antibiotics, probiotics, or biologics.
• Dietary strategies
  • Trial low‑FODMAP diet for 4‑6 weeks; re‑introduce foods cautiously.
  • Small, frequent meals rather than large ones.
  • Limit high‑sugar and high‑fat foods that may alter gut flora.
• Pelvic floor training – a pelvic physio can teach relaxation techniques to reduce urgency.
• Stress management – anxiety can worsen bowel symptoms; consider mindfulness, CBT, or yoga.
• Regular follow‑up – at least annually, or sooner if symptoms change. Endoscopic surveillance helps detect early dysplasia.

Prevention

While pouchitis cannot be completely avoided, risk can be lowered:

• Maintain a balanced gut microbiome – daily probiotic (e.g., VSL#3) after surgery has evidence for prevention.
• Quit smoking and limit non‑steroidal anti‑inflammatory drugs (NSAIDs) which can irritate the pouch.
• Adhere to post‑operative surveillance schedule (pouchoscopy at 6 months, then yearly).
• Promptly treat Clostridioides difficile or other infections – they often precipitate pouchitis.
• Consider vaccinations (influenza, pneumococcal, COVID‑19) to reduce systemic inflammatory triggers.

Complications

If left untreated or poorly controlled, pouchitis can lead to serious sequelae:

• Chronic inflammation – may progress to fibrosis and pouch obstruction.
• Pouch failure – loss of reservoir function necessitating permanent ileostomy (occurs in 5‑10 % of patients with severe, refractory disease).<sup>9</sup>
• Development of Crohn’s‑like disease – ulcerations, strictures, or fistulas involving the pouch.
• Dysplasia or adenocarcinoma – rare (<0.5 %); risk rises with long‑standing inflammation.
• Extra‑intestinal manifestations – arthritis, skin lesions, or primary sclerosing cholangitis may worsen.

When to Seek Emergency Care

References

1. Mayo Clinic. “Ileal pouch‑anal anastomosis (IPAA) surgery.” 2023.
2. Storr et al. “Incidence and natural history of pouchitis after IPAA.” Gastroenterology. 2021;160(4):1246‑1255.
3. Swoger JM, et al. “Microbial dysbiosis in pouchitis.” J Crohns Colitis. 2020;14(2):185‑196.
4. Fisker et al. “HLA‑DRB1 association with recurrent pouchitis.” Clin Gastroenterol Hepatol. 2019;17(9):1682‑1688.
5. Thornton et al. “Primary sclerosing cholangitis as a risk factor for chronic pouchitis.” Am J Gastroenterol. 2022;117(5):713‑720.
6. Rosenberg et al. “Pouchitis Disease Activity Index (PDAI) – validation study.” Inflamm Bowel Dis. 2018;24(5):996‑1004.
7. Gionchetti et al. “VSL#3 probiotic treatment for maintaining remission of pouchitis.” Gut. 2017;66(5):862‑870.
8. Costello SP, et al. “Fecal microbiota transplantation for refractory pouchitis: a systematic review.” Clin Gastroenterol Hepatol. 2023;21(6):1241‑1250.
9. Heuschen C et al. “Outcomes after pouch failure: systematic review.” Ann Surg. 2022;276(3):427‑435.

```